Shots: The approval is based on the P-III STOP 301 trial evaluates Trudhesa (0.725 mg/spray) in 5650+ patients with migraine with or without aura for 24 or 52 wks. The […]readmore
Tags : nasal spray
Shots: Glenmark is concluding the final, national phase of its MAA process to enable launch of its innovative nasal spray, Ryaltris (olopatadine hydrochloride, 665mcg and mometasone furoate, 25mcg), in 17 […]readmore
Shots: Glenmark to receive up front, regulatory & commercial milestones along with royalties on sales of Ryaltris in the licensed territory. Glenmark will continue the development of the therapy and […]readmore
Shots: Pherin will receive $2.25M of unregistered common stock (1,630,435 unregistered shares) from Vista VistaGen has rights to commercialize and develop PH94B nasal spray (expected to enter in P-III in […]readmore